trial
as of 2026-07-01A Pharmacokinetic Study of MP-214 in Patients With Schizophrenia
NCTId NCT01626859
at a glance
Phase 2, Phase 3 · Completed
Enrollment 38 (actual)
Sponsored by Tanabe Pharma Corporation
Primary completion 2013-08
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 2, Phase 3
Status
Completed
Enrollment
38 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2012-05
Primary completion
2013-08
Eligibility
ALL · 20 Years · 64 Years
Interventions & indications
Sponsors
Tanabe Pharma CorporationLead Sponsor
Sites
0 total
Linked catalysts
1
Facts & assertions
4 sourced
Enrollment
38
Phase
PHASE2,PHASE3
Primary Completion Date
2013-08
Status
COMPLETED
relationships
The graph out of here
drug
lead_sponsor
company
indication